Stockscreener 앱 받기
122.06
3.73%
4.39
시간 외 거래:
122.06
전일 마감가:
$117.67
열려 있는:
$119.03
하루 거래량:
779.35K
Relative Volume:
0.92
시가총액:
$10.15B
수익:
$51.48M
순이익/손실:
$-315.00M
주가수익비율:
-34.18
EPS:
-3.5708
순현금흐름:
$-244.00M
1주 성능:
+7.87%
1개월 성능:
+1.89%
6개월 성능:
+56.67%
1년 성능:
+139.29%
1일 변동 폭
$117.88
$122.37
1주일 범위
$112.88
$122.37
52주 변동 폭
$50.35
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
122.06 | 9.56B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-06 | 개시 | Canaccord Genuity | Buy |
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada
KYMR Upgraded by Wolfe Research -- Rating Raised to Outperform - GuruFocus
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Five September events will webcast Kymera live - Stock Titan
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - investingnews.com
A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan
Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target - Kalkine Media
KYMR Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program - Investing.com Nigeria
Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P. - MarketBeat
Wellington Management Group LLP Trims Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
119,503 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by The Manufacturers Life Insurance Company - MarketBeat
Freestone Grove Partners LP Purchases New Shares in Kymera Therapeutics, Inc. $KYMR - MarketBeat
20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY - MarketBeat
Kymera Therapeutics Inc. (KYMR) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Boone Capital Management LLC Purchases Shares of 113,173 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 149,908 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Stock Holdings Increased by Odyssean LLC - MarketBeat
Nicholas Investment Partners LP Invests $6.26 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc. - MarketBeat
Deutsche Bank AG Makes New $12.16 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
B of A, Truist raise Kymera Therapeutics price targets - scanx.trade
Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.15%
자본화:
|
볼륨(24시간):